Similar articles

• Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer.

  Hung MC, Hortobagyi GN, Ueno NT. Hung MC, et al. Adv Exp Med Biol. 2000;465:171-80. doi: 10.1007/0-306-46817-4_16. Adv Exp Med Biol. 2000. PMID: 10810625 Review. No abstract available.
• A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer.

  Hortobagyi GN, Hung MC, Lopez-Berestein G. Hortobagyi GN, et al. Hum Gene Ther. 1998 Aug 10;9(12):1775-98. doi: 10.1089/hum.1998.9.12-1775. Hum Gene Ther. 1998. PMID: 9721088 Clinical Trial. No abstract available.
• E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy.

  Ueno NT, Yu D, Hung MC. Ueno NT, et al. Breast Cancer. 2001;8(4):285-93. doi: 10.1007/BF02967526. Breast Cancer. 2001. PMID: 11791119
• Recent advances in breast cancer research: from genes to management.

  Hendrix MJ, Muschel RJ, Padarathsingh M. Hendrix MJ, et al. Am J Pathol. 1997 Sep;151(3):883-8. Am J Pathol. 1997. PMID: 9284837 Free PMC article. No abstract available.
• The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A.

  Yu D, Hung MC. Yu D, et al. Cancer Metastasis Rev. 1998 Jun;17(2):195-202. doi: 10.1023/a:1006054421970. Cancer Metastasis Rev. 1998. PMID: 9770116 Review. No abstract available.